Immunomedics, Inc. (NASDAQ:IMMU) Director Cynthia L. Goldenberg sold 40,000 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $9.24, for a total value of $369,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Immunomedics, Inc. (IMMU) traded down 2.81% during midday trading on Friday, reaching $10.38. The company’s stock had a trading volume of 5,088,650 shares. Immunomedics, Inc. has a one year low of $2.02 and a one year high of $10.99. The stock’s market cap is $1.16 billion. The stock’s 50 day moving average price is $8.59 and its 200-day moving average price is $7.06.

Immunomedics (NASDAQ:IMMU) last announced its earnings results on Wednesday, August 16th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.13. The business had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.75 million. The company’s revenue was down 31.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) EPS. On average, analysts forecast that Immunomedics, Inc. will post ($0.55) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Immunomedics, Inc. (IMMU) Director Cynthia L. Goldenberg Sells 40,000 Shares” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/25/immunomedics-inc-immu-director-cynthia-l-goldenberg-sells-40000-shares.html.

A number of equities analysts recently commented on the company. BidaskClub raised Immunomedics from a “hold” rating to a “buy” rating in a report on Wednesday. Jefferies Group LLC set a $11.00 price target on Immunomedics and gave the company a “buy” rating in a report on Thursday, August 17th. Zacks Investment Research cut Immunomedics from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Cowen and Company reissued an “outperform” rating and set a $15.00 price target on shares of Immunomedics in a report on Monday, July 24th. Finally, ValuEngine raised Immunomedics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $12.00.

Institutional investors have recently made changes to their positions in the company. Amalgamated Bank boosted its position in shares of Immunomedics by 8.1% in the second quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 966 shares during the last quarter. Stephens Inc. AR acquired a new position in shares of Immunomedics during the second quarter worth about $115,000. Raymond James Financial Services Advisors Inc. boosted its position in shares of Immunomedics by 11.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,473 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Immunomedics by 99.3% in the second quarter. SG Americas Securities LLC now owns 20,719 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 10,323 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC acquired a new position in shares of Immunomedics during the first quarter worth about $137,000. Institutional investors own 63.39% of the company’s stock.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Stock Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related stocks with our FREE daily email newsletter.